Overview and Scope
Hepatic encephalopathy is a condition characterized by a decline in brain function resulting from severe liver disease. It is a reversible syndrome of impaired brain function in patients with advanced liver diseases. Treating hepatic encephalopathy (HE) involves managing the underlying liver disease, reducing ammonia levels in the blood and addressing neurological symptoms.
Sizing and Forecast
The hepatic encephalopathy market size has grown strongly in recent years. It will grow from $1.62 billion in 2023 to $1.72 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to prevalence of liver diseases, growing awareness about hepatic encephalopathy, government initiatives, increasing new liver therapies.
The hepatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.1 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing ageing population, surge in treatment options, rising expenditure on healthcare infrastructure, investments on hepatic encephalopathy treatments. Major trends in the forecast period include launch of emerging therapies, research and clinical trials, advances in liver transplantation, pharmaceutical innovations, advances in nutrition and dietary management, adption of telemedicine and remote monitoring.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report
Segmentation & Regional Insights
The hepatic encephalopathy market covered in this report is segmented –
1) By Drug Class: Antibiotics; Laxatives; L-Ornithine; L-Aspartate; Other Drug Classes
2) By Route Of Administration: Oral; Intravenous; Rectal
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
North America was the largest region in the hepatic encephalopathy market in 2023. The regions covered in hepatic encephalopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12906&type=smp
Major Driver Impacting Market Growth
The growing prevalence of liver diseases is expected to propel the growth of the hepatic encephalopathy market going forward. Liver disease is a medical condition affecting the liver and impairing its function. Liver disease treatments such as hepatic encephalopathy can alleviate symptoms, slow disease progression, improve liver function and reduce hepatic encephalopathy occurrences by improving the management of underlying conditions, potentially reducing frequency and severity and enhancing patients’ overall quality of life. For instance, in March 2023, according to the Office For Health Improvement And Disparities, a UK-based government organization, premature deaths from liver disease increased by 3.7% in 2021 from 10,501 to 10,127 in 2020. Therefore, the growing prevalence of liver diseases drives the hepatic encephalopathy market.
Key Industry Players
Major players in the hepatic encephalopathy market are Umecrine Cognition AB, Bausch Health Companies Inc., Mallinckrodt Pharmaceuticals, Lupin Limited, Salix Pharmaceuticals, Norgine B.V., Ferring B.V., ASKA Pharmaceutical Co. Ltd., Vedanta Biosciences Inc., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Ochsner Health Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Amneal Pharmaceuticals LLC, Mallinckrodt PLC, Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., ASKA Pharmaceutical Co. Ltd., Norgine B.V.
The hepatic encephalopathy market report table of contents includes:
1. Executive Summary
2.Hepatic Encephalopathy Market Characteristics
3.Hepatic Encephalopathy Market Trends And Strategies
4.Hepatic Encephalopathy Market analysis
5.Hepatic Encephalopathy Market Size And Growth
6.Hepatic Encephalopathy Segmentation
7.Hepatic Encephalopathy Regional And Country Analysis
.
.
.
27.Hepatic Encephalopathy Competitive Landscape And Company Profiles
28.Hepatic Encephalopathy Key Mergers And Acquisitions
29.Hepatic Encephalopathy Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Umecrine Cognition AB
- Bausch Health Companies Inc.
- Mallinckrodt Pharmaceuticals
- Lupin Limited
- Salix Pharmaceuticals
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
